Questa traduzione è in preparazione. Nel frattempo mostriamo temporaneamente la versione originale in inglese.
Imprese · 02/05/20231 min di lettura
A Risk-Based Approach to Monitoring of Clinical Investigations-Questions and Answers; Guidance for Industry; Correction
Traduzione automatica locale · Lingua originale della fonte
Riepilogo
The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register of April 12, 2023. The document announced the availability of a final guidance entitled "A Risk-Based Approach to Monitoring of Clinical Investigations--Questions and Answers; Guidance for Industry." The notice of availability for this final guidance was published with an incorrect OMB control number. This document corrects that error.
Lingua originale della fonte: Federal Register — Food and Drug AdministrationApri il comunicato originale →